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Introduction: Metastatic renal cell carcinoma (mRCC) is incurable, with an estimated five-year survival of 12.3%. 
Type 2 diabetes mellitus (T2DM) has not been validated as a risk factor or poor prognostic factor in RCC, but its 
provascular pathophysiology has been associated with upregulation of growth factors that are also implicated in 
RCC. This study evaluated the impact of T2DM on time to metastatic disease in RCC, progression-free survival 
(PFS) and overall survival (OS). 
 
Patients and Methods: Patients at least 18 years of age were included in this single-health system retrospective 
cohort study if they had been treated at UNC Medical Center Healthcare System for mRCC between March 1, 
2014 and March 1, 2019. Time from diagnosis to progression to metastatic disease, PFS, and OS were compared 
between patients with T2DM and patients without T2DM. PFS and OS was further compared between patients 
who initially presented with localized disease and those who presented with de novo metastatic disease in both 
the T2DM and non-T2DM arms.  
 
Results: A total of 147 mRCC patients were included in the study cohort (n=27 with T2DM and n=120 without 
T2DM). Among patients who initially presented with localized disease, a significantly shorter time to mRCC was 
observed in patients with T2DM (11.4 vs 33.2 months, HR 2.41, 95% CI 1.16-4.99; P=0.0006). However, 
significant differences in PFS (23.4 vs 14.6 months, HR 0.78, 95% CI 0.5-1.25; P=0.32), OS (58.6 vs 48.3 months, 
HR 0.86, 95% CI 0.48-1.54; P=0.63), and the prevalence of mRCC at time of initial diagnosis (P=0.29) were not 
observed.  
 
Conclusions: Patients with T2DM have a 2.4-fold higher risk of progressing to mRCC than non-T2DM patients. 
But, patients with T2DM were not more likely to be diagnosed with mRCC on initial presentation, and T2DM 
did not impact either PFS or OS. These data require future validation; however, the decreased time of progression 
to mRCC in the T2DM arm suggests that patients with T2DM may benefit from more diligent monitoring after a 
localized RCC diagnosis.  
Introduction 
Renal cell carcinoma (RCC) ranks among the top ten most commonly diagnosed cancers for both men 
and women in the United States (U.S.) with an estimated 73,750 new diagnoses in 2020.1 Localized RCC is 
generally curable with surgery, with a 5-year survival rate of 92%. In contrast, metastatic RCC (mRCC) remains 
incurable, and traditional treatment modalities (e.g., cytotoxic chemotherapy and radiation) have limited use.2,3 
Instead, treatments for mRCC include orally administered targeted therapies and immunotherapy. Agents 
available to mRCC patients include orally-administered multikinase inhibitors of the vascular endothelial growth 
factor (VEGF)–pathway and the mammalian target of rapamycin (mTOR).4–7 Immunotherapeutic options include 
inhibitors of the programmed cell death receptor 1 (PD-1) and cytotoxic T lymphocyte-associated antigen 4 
(CTLA-4) checkpoints.8 Recently, combination therapy has also been approved by the U.S. Food and Drug 
Administration (FDA). These options include combined targeted therapy (lenvatinib plus everolimus)9, combined 
immunotherapy (ipilimumab plus nivolumab)10, and combined immunotherapy plus targeted therapy 
(pembrolizumab plus axitinib or avelumab plus axitinib)11,12. Despite these therapeutic options, the 5-year 
survival rate in patients with mRCC is only 12.3%.13  
Clear cell is the most common histologic subtype of RCC, making up approximately 80% of all cases.14 
Clear cell RCC (ccRCC) is most often caused by a mutation in the von Hippel-Lindau tumor suppressor gene 
(VHL) located on chromosome 3p25, which encodes the VHL protein (pVHL). In a normally functioning cell, 
pVHL contributes to the regulation of a cell’s response to oxygen by binding to hypoxia-inducible factor-1 alpha 
(HIF-1𝛼𝛼) and marking it for degradation. This prevents HIF-1𝛼𝛼 from activating genes responsible for anaerobic 
metabolism in an oxygen-rich environment.15,16 Mutated pVHL in unable to bind to HIF-1𝛼𝛼, leading to 
inappropriate accumulation of HIF-1𝛼𝛼, which results in aberrant activation of genes that promote tumorigenesis 
and angiogenesis,15,16 and results clinically in a highly vascularized tumor.17 
Type 2 diabetes mellitus (T2DM) is a metabolic disorder characterized by macrovascular and 
microvascular complications that contribute to the morbidity and mortality of the disease. Persistent and chronic 
hyperglycemia commonly observed in T2DM has been associated with macrovascular complications, such as 
cardiovascular disease and stroke, as well as microvascular complications that include nephropathy, retinopathy, 
and peripheral neuropathy.18 T2DM-induced hyperglycemia has been shown to induce intracellular and 
extracellular changes through activation of protein kinase C in vascular tissues that ultimately result in both 
cellular damage and increased expression of multiple growth factors that are also oncogenic drivers of metastatic 
ccRCC, including VEGF, endothelin 1, transforming growth factor ß (TGF-β), connective tissue growth factor, 
and collagen types IV and VI.19 In addition to its microvascular and macrovascular complications, T2DM has 
also been associated with increased cancer risk and decreased survival in patients with colon, breast, pancreatic, 
and endometrial cancer.20 
Despite the underlying disease pathophysiology of both T2DM and ccRCC being linked to the VEGF 
pathway, T2DM has not been validated as a risk factor for ccRCC or as a prognostic factor in mRCC in 
prospective studies.21 However, retrospective studies have linked T2DM and RCC, including a previous meta-
analysis of RCC patients with T2DM found that these patients experience worse overall survival and progression 
free survival.22 It is difficult to establish whether it is truly T2DM contributing to this survival difference because 
many patients also suffer from hypertension and obesity which are validated risk factors for RCC.23 Therefore, 
we conducted a single institution retrospective cohort study to test that hypothesis that T2DM is a negative 
predictor of time from localized disease to mRCC, PFS and OS in patients who received systemic 
pharmacotherapy for treatment of mRCC.  
 
Methods 
Study Design and Data Collection 
This was a single health system retrospective cohort study approved by the University of North Carolina 
Institutional Review Board (IRB 19-0267). The Carolina Data Warehouse for Health (CDW-H), a central data 
repository containing clinical, research, and administrative data sourced from the UNC Health Care System, was 
queried to identify eligible patients between March 1st 2014 and March 1st, 2019. Patients were identified using 
the ICD9 code 189 and ICD10 code C64 for kidney cancer. All patients with kidney cancer diagnosis were 
evaluated by chart review to verify that they had a clear cell histology and to determine if they had metastatic 
disease. Those with confirmed mRCC by ICD9/10 codes were then stratified based on the presence of a T2DM 
diagnosis using ICD9 code 250 and ICD10 code E11 for T2DM. While it was not a prerequisite for a T2DM 
diagnosis to precede an RCC diagnosis, patients were excluded from this study if they were treated for mTOR 
inhibitor-induced T2DM and/or hyperglycemia. Data was extracted from the health system electronic medical 
record. Additional T2DM patients not initially identified by ICD9/10 codes because they did not receive diabetes 
care at UNC Health Care System were identified by chart review. Eligible patients were included if they were at 
least 18 years of age, were diagnosed with histologically confirmed ccRCC, had radiologic documentation of 
progression to metastatic disease, and had a primary medical oncologist within the UNC Health Care System. 
Patients were excluded if they were diagnosed with a second primary malignancy that required concurrent 
chemotherapy or did not receive systemic treatment for their metastatic disease as this study was designed to 
evaluate the impact of T2DM on prognosis in the setting of appropriate systemic pharmacotherapy. Manual chart 
review was utilized to determine patient demographics (e.g., age, sex, race), baseline laboratory values, treatment 
details (e.g., medications, doses, dose adjustments and treatment discontinuation dates), as well as cancer specific 
details (e.g., date of diagnosis, stage at diagnosis, prior nephrectomy or radiation, location of metastases). 
Information regarding T2DM medication regimens was also collected.  
 
Endpoints 
The primary endpoint for this study was progression-free survival (PFS), defined as time from RCC 
diagnosis (date of biopsy confirming mRCC) until evidence of radiologic progression, a provider note 
documenting clinical/provider-assessed progression, or cancer-related death in patients with and without T2DM.  
Secondary study endpoints included overall survival (OS), defined as time from diagnosis of mRCC until time of 
death from any cause, and time to from localized ccRCC diagnosis until radiologic evidence of mRCC. PFS and 
OS from initial diagnosis with localized RCC was also evaluated. All study primary and secondary endpoints 
were compared between mRCC patients with T2DM and mRCC patients without T2DM. PFS and OS was 
compared between T2DM and non-T2DM patients initially dignosed with localized RCC as well as between 
T2DM and non-T2DM patients diagnosed with de novo metastatic disease. For PFS, patients were censored from 
time-to-event analyses if they were lost to follow-up, were switched to a subsequent pharmacotherapeutic agent 
prior to evidence of progression, were alive at the end of the study with no evidence of progression, or died of a 
non-cancer related cause before evidence of progression. Patients were censored for OS if they were lost to follow-
up or were still alive at the end of the study. No patients were censored in the time to mRCC analyses. Patients 
who were lost to follow-up after transitioning to hospice were censored on the date of hospice admission or last 
clinical note while in hospice. 
 
Statistical Analysis 
The overall study cohort was characterized using descriptive statistics. Categorical variables (race, sex, 
smoking status, IMDC prognostic risk, metastatic sites, prior nephrectomy, prior radiation, and mRCC diagnosis 
at initial presentation) were summarized as counts and percentages and continuous variables (age, time to mRCC 
diagnosis, PFS, OS) were summarized as means (with standard deviation) or medians (with range), as appropriate. 
Inferential statistical testing was two-sided with an a priori selected significance (alpha) level of 0.05 (P<0.05). 
Log rank tests were used in univariate survival analyses of PFS, OS, and time to metastases, and served as the 
basis of Kaplan Meier plots. Time to metastases was compared between patients initially diagnosed with localized 
RCC in the non-T2DM and T2DM arms. Subgroup analysis was performed based on stage of RCC at time of 
initial diagnosis (localized disease vs de novo metastatic disease). For all survival analyses, Cox proportional 
hazards were used to estimate hazard ratios (HR) and 95% confidence intervals (CI). To evaluate the prevalence 
of mRCC diagnosis on initial presentation between T2DM and non-T2DM ccRCC patients, odds ratios (OR) and 
95% CIs were derived using logistic regression. Baseline characteristics did not differ significantly between the 
two arms so multivariable analysis was not performed. Statistical analyses were performed using SAS JMP Pro 
14.0.0 (SAS Institute, Cary, NC, USA) and Kaplan Meier plots were generated using GraphPad Prism version 




A summary of the screening, inclusion and analysis strategies is included in Figure 1. A total of 3,165 
patients with an ICD9 or ICD10 code for malignant neoplasm of the kidney and who underwent at least one 
clinician visit within the UNC Health Care System between March 1, 2014 and March 1, 2019 were screened for 
inclusion. A total of 840 patients were excluded for diagnosis of a malignancy other than RCC, 1,901 patients 
were excluded for only having localized disease and with no evidence of progression to mRCC, and 44 patients 
who were diagnosed with a non-ccRCC histologic subtype (e.g., chromophobe, papillary, etc.) were also 
excluded. Among the 380 potentially eligible metastatic ccRCC patients, 31 were excluded because they 
presented with an additional concurrent primary malignancy that required pharmacotherapeutic treatment, 132 
were excluded because their primary medical oncologist was not in the UNC Health Care System, and 70 were 
excluded because they opted not to receive systemic pharmacotherapy for their mRCC. A total of 147 mRCC 
patients were included in the final analyses, which included 120 mRCC patients without a T2DM diagnosis and 
27 mRCC patients with T2DM.  
 
Baseline Characteristics  
A summary of baseline clinical and demographic characteristics is provided in Table 1. The median age 
at time of inial RCC diagnosis was 59.5 years-old among patients without T2DM, and 65.0 years-old among 
patients with T2DM. A majority of the patients in both arms were male (71% in the non-T2DM arm vs 67% is 
the T2DM arm), and White (83% in the non-T2DM arm vs 74% in theT2DM arm). Numerically there was a 
higher percentage of current smokers in the T2DM arm (26% vs 11%), and a higher percentage of former smokers 
in the non-T2DM arm (52% vs 30%). IMDC risk scores were similar between the two arms. IMDC risk score 
was not reported for 29 patients in the non-T2DM arm and 8 patients in the T2DM arm due to baseline labs that 
were not accessable in the current electronic medical record. A majority of patients had a prior nephrectomy (60% 
in the non-T2DM arm vs 67% in theT2DM arm) and a majority had evidence of metastatic disease in multiple 
sites (85% in both arms), with the lungs being the most common site of metastases (72% in the non-T2DM arm 
vs 78% in T2DM arm).    
The distribution of first-line systemic pharmacotherapies is reported in Figure 2A. The most common 
first-line treatment among all study cohort patients was monotherapy with a VEGF inhibitor (n=103 or 70.1% of 
all study patients). VEGF inhibitors prescribed to patients include pazopanib, sunitinib, cabozantinib, sorafenib, 
and axitinib. Pazopanib was the most commonly prescribed VEGF inhibitor in the T2DM arm and the non-T2DM 
arm (n=14 or 51.9% of T2DM patients, and n=53 or 44.2% of non-T2DM patients). The second most common 
first-line regimen was immunotherapy (n=27 or 18.3% of all study patients), either as nivolumab monotherapy or 
ipilimumab plus nivolumab combination therapy. Combination ipilimumab plus nivolumab was the most 
common immunotherapy regimen prescribed in the T2DM arm and the non-T2DM arm (n=4 or 14.8% of T2DM 
patients and n=15 or 12.5% of non-T2DM patients respectively). No patients in the T2DM arm were prescribed 
HD IL-2 therapy. For the patients T2DM arm, their antidiabetic medication regimens were recorded at the time 
of initiation their first-line treatment regimen for their mRCC. The most common two medication classes 
prescribed were either a biguanide (i.e., metformin), or a sulfonylurea (i.e., glipizide, glimepiride), and were 
28.2% (n=11) and 23.2% (n=9), respectively (Figure 2B). Last, 33.3% (n=9) were prescribed multiple antidiabetic 
medications at time of first-line mRCC treatment initiation. 
 
Time to mRCC, PFS and OS 
 Out of the 147 patient-cohort, 68 (46.2%) were diagnosed with mRCC at the time of initial presentation. 
When the patient group was separated based on T2DM status, 10 patients with T2DM and 58 patients without 
T2DM (37% vs 48.3%, respectively) were diagnosed with metastatic disease at baseline (Figure 3A). A significant 
difference in the prevalence of mRCC diagnosis at the time of initial presentation was not observed between 
T2DM and non-T2DM patients (OR=0.63, 95% CI 0.27-1.44; P=0.29) (Figure 3A). Among patients who were 
not diagnosed with metastatic disease at the time of initial presentation, the time to mRCC diagnosis was 
significantly longer in the non-T2DM patients (median 33.2 months) compared to the T2DM arm (11.4 months) 
(HR=2.41, 95% CI 1.16-4.99; P=0.0006) (Figure 3B). For both PFS and OS, significant associations between 
T2DM and survival were not observed. Median PFS was 23.4 months in the T2DM arm and 14.6 months in the 
non-T2DM arm (HR=0.78, 95% CI 0.5-1.25; P=0.32) (Figure 3C). Median OS was 58.6 months in the T2DM 
arm and 48.3 months in the non-T2DM arm (HR=0.86, 95% CI 0.48-1.54; P=0.63) (Figure 3D). A significant 
difference in PFS or OS was not observed when the T2DM and non-T2DM arms were further broken down into 
localized and de novo metastatic subgroups. Median OS from date of diagnosis with localized RCC was 76.2 
months in the non-T2DM group and 44.5 months in the T2DM group (P=0.19) (Figure 4A). For patients initially 
diagnosed with localized RCC, median OS from time of diagnosis with mRCC was 37.8 months in the non-T2DM 
group and 32.0 months in the T2DM group (P=0.65) (Figure 4B). Median PFS in this subgroup of patients was 
18.0 months in non-T2DM patients and 13.3 months in T2DM patients (P=0.61) (Figure 4C). In patients 
diagnosed with de novo metastatic RCC, median OS was 14.7 months in the non-T2DM arm and 24.1 months in 
the T2DM arm (P=0.31) (Figure 4D). Median PFS in this subgroup was 9.5 months in the non-T2DM arm and 
15.8 months in the T2DM arm (P=0.35) (Figure 4E).  
 
Discussion 
Despite significant improvements in the treatment landscape for mRCC over the past decade, which include 
U.S. FDA approval of VEGF-pathway inhibitors, mTOR inhibitors, and immunotherapy, survival outcomes for 
mRCC remain poor with a 5-year survival of 12.3%. Selection of initial therapy is guided by IMDC risk score; 
however, there is a lack of predictive biomarkers that may help predict a patient’s response to treatment.24  
Additionally, comorbidities have been evaluated in determining an individual’s risk of developing RCC, but 
minimal data suggests whether certain comorbidities confer a worse prognosis. Currently, it is unclear whether 
RCC patients with T2DM are more likely to suffer worse survival outcomes than RCC patients without T2DM. 
This study evaluated the effects of T2DM on time to mRCC after initial diagnosis, and on survival (i.e., PFS and 
OS). The results of this study are important because they serve to clarify the impact of T2DM on mRCC time to 
the development of metastatic disease, but also PFS and OS.  
When evaluating whether patients present initially with more serious RCC, we did not observe a significant 
association between incidence of de novo metastatic disease (Stage IV) among patients with T2DM versus those 
without T2DM (37% vs 48.3%, P=0.29). However, there we did observe a statistically significant association 
between T2DM and time from diagnosis with localized RCC (Stage I-III) to evidence of progression to mRCC, 
where we found that patients with T2DM progressed to metastatic disease nearly 2.5-times faster than those 
without T2DM (median 11.4 months vs 33.2 months; HR=2.41, 95% CI 1.16-4.99; P=0.0006). This could be due 
to the provascular impacts of T2DM where hyperglycemia drives the expression of growth factors potentially 
leading to tumorigenesis.19 Microvascular damage caused by high blood glucose, resulting in cellular damage, 
could also drive an inflammatory process contributing to the development of metastatic disease. While T2DM 
has not been shown to increase the incidence of RCC, these results suggest that T2DM may increase the risk of 
developing metastatic disease as it significantly shortens the time from diagnosis of localized disease to 
progression to metastatic disease.  
While we observed a positive association between T2DM and time to evidence of metastatic disease, our data 
do not support the hypothesis that T2DM impacts PFS or OS. We did not observe significant associations between 
T2DM and non-T2DM for either PFS or OS (P=0.32 and P=0.63, respectively). No differences in PFS and OS 
were observed when the non-T2DM and T2DM groups were further analyzed in initial subgroups of patients 
diagnosed with localized RCC or de novo mRCC. This suggests that T2DM itself is likely not predictive of drug 
response or efficacy in the setting of mRCC. However, given that metformin has recently gained notoriety as a 
potential anticancer agent, 25–27 these findings suggest that T2DM would likely not be a confounding variable if 
the impact of metformin were to be evaluated as a pharmacotherapeutic treatment option in RCC. Significant 
differences in pharmacologic treatment of mRCC were not observed between the T2DM and non-T2DM arm, 
suggesting that the type of pharmacologic treatment for mRCC was also not a confounding factor. While this 
study did not observe differences PFS and OS between mRCC patients with T2DM and mRCC patients without 
T2DM, these results contribute to the overall body of knowledge because few studies have evaluated whether 
T2DM patients have worse outcomes in mRCC.22  
This study was limited by the fact that the overall cohort was smaller than anticipated, and only 18% of the 
study cohort had a T2DM diagnosis. The small study cohort was surprising given that approximately 20-40% of 
patients progress to metastatic disease following nephrectomy.28 The small study cohort could be a result of the 
large proportion of patients that were missing pathologic information necessary for inclusion (i.e., missing 
histologic subtype) or patients that were lost to follow up after nephrectomy. There was also a substantial number 
of patients who did not receive their primary cancer care at UNC and instead were only seen at UNC to seek a 
second opinion or consult on their care. Approximately 80% of the screened patients with complete pathological 
reports had clear cell histology which is consistent with the general population.14 Because the goal of this study 
was to follow patients with metastatic ccRCC from treatment with systemic pharmacotherapy until progression, 
there were 70 patients with metastatic ccRCC; however, they were not included in the final cohort because they 
were not treated with systemic pharmacotherapy. Instead, these patients were either treated with radiation or 
surgery, opted for surveillance, or went directly to hospice care.  
While relevant covariates were not identified and included in multivariable models, it is possible that the 
modest sample size of T2DM patients in this study could have obscured a true covariate effect on the primary and 
secondary endpoints. Moreover, the significant association observed with time to progression to mRCC could 
realistically be skewed by factors like IMDC risk score or smoking status in the real world. In addition, comorbid 
hypertension, and BMI were not recorded for the study cohort, which is a limitation of this study because they 
could have been potential covariates since these are common risk factors for developing RCC. While unlikely, it 
is also possible that by controlling for covariates (e.g., IMDC risk, smoking status, BMI), could impact PFS and 
OS results between the two arms. Last, consistent with the nature of retrospective studies, there were a number 
of patients with missing or incomplete labs that prevented full IMDC risk evaluation which could impact future 
multivariate analyses.  
Given a small study cohort and disproportionate sizes of the two study arms, it is important that these results 
be validated prospectively in an independent, external cohort of patients. A prospective study following non-
diabetic RCC patients and RCC patients with T2DM from time of initial diagnosis to diagnosis with metastatic 
disease could further confirm these results. Alternatively, if this study was expanded to include retrospective data 
from multiple health systems in order to evaluate data from a cohort with a larger sample size, that could also be 
an approach to confirm these study results. Additionally, our data cannot inform whether or not blood glucose 
levels themselves correlate to prognosis in RCC, as we did not collect data about disease control in subjects with 
T2DM.  
Currently, there are a limited number of retrospective studies that have evaluated whether metformin confers 
a survival benefit in RCC, but the results of these studies are difficult to interpret in the absence of prospective 
trials evaluating the effect of T2DM as a disease on RCC prognosis.25,27 Phase I and phase II trials evaluating 
metformin in combination with other anti-cancer agents are already underway in other types of cancer.29 Lastly, 
since it was found that patients with T2DM progress to metastatic disease significantly faster than non-diabetic 
RCC patients, it is worth evaluating whether these patients require more intensive surveillance or adjuvant 
treatment. Historically, adjuvant treatment has not shown benefit over placebo in RCC and is not currently 
recommended outside of participation in a clinical trial.30,31 However, it is worth evaluating whether adjuvant 
treatment, potentially even with metformin, may provide benefit in T2DM patients. 
In conclusion, this study suggests that T2DM is not a negative prognostic factor in mRCC. This was evidenced 
by the lack of difference in PFS and OS between the T2DM arm and the non-diabetic arm of the study cohort. 
Importantly, however, this study did show that patients with T2DM progress to metastatic disease almost 3 times 
faster than non-diabetic patients. While these results need to be validated with future prognostic studies, they 
provide rational for future evaluation into adjuvant treatment in patients with T2DM or for evaluation of 
metformin as an anticancer agent in mRCC patients regardless of diabetic status.  
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Tables and Figures 
Table 1. Patient baseline clinical and demographic characteristics by T2DM status. Baseline clinical and 
demographic characteristics are included for 147 patients included in the final analysis. Clinical and demographic 
characteristics were evaluated between the T2DM arm and the non-T2DM arm. One patient in the non-T2DM 
arm and one patient in the T2DM arm identified as both Hispanic and White. Abbreviations: IMDC, international 
metastatic renal cell carcinoma database consortium; mRCC, metastatic renal cell carcinoma; T2DM, type 2 
diabetes mellitus. 
 
Characteristic Non-T2DM arm (n=120) T2DM arm (n=27)  P-Value 
Age, median years (range) 65 (37-97) 68 (51-83) 0.14 
Sex, n (%) 0.67 
  Male 85 (71) 18 (67)  
  Female  35 (29) 9 (33)  
Race and Ethnicity, n (%) 0.11 
  White 100 (83) 19 (70)  
  Black 13 (11) 6 (22)  
  Native American 2 (2) 1 (4)  
  Hispanic 6 (5) 1 (4)  
  Not reported  0 (0) 1 (4)  
Smoking Status, n (%)  
  Never Smoker 43 (36) 12 (44) 0.06 
  Former Smoker 62 (52) 8 (30)  
  Current Smoker 13 (11) 7 (26)  
IMDC Prognostic Risk, n (%) 0.57 
  Favorable  30 (25) 6 (22)  
  Intermediate 30 (25) 9 (33)  
  Poor 31 (26) 4 (15)  
  Not Reported 29 (24) 8 (30)  
Metastatic sites, n (%) 0.98 
  Lung  86 (72) 21 (78)  
  Lymph node 62 (52) 12 (44)  
  Bone 49 (41) 8 (30)  
      Liver 26 (22) 5 (19)  
  Adrenal gland 22 (18) 4 (15)  
1 organ with metastasis, n (%) 18 (15) 4 (15) 0.99 
>2 organs with metastases, n (%)s 102 (85) 23 (85) 0.99 
Prior Nephrectomy, n (%) 73 (61) 18 (67) 0.67 
Prior Radiation, n (%) 30 (25) 5 (19) 0.62 
mRCC diagnosis at initial 
presentation, n (%) 
58 (48) 10 (37) 0.29 
  
Figure 1. Study schematic. A total of 3,165 potentially eligible patients were identified. Eligible patients were 
initially identified using ICD9 and ICD10 codes. Following multiple rounds of screening and evaluation, the final 
study cohort was comprised of 147 patients. Abbreviations: ccRCC, clear cell renal cell carcinoma RCC, renal 





Figure 2. Distribution of first-line mRCC and T2DM medications. Panel A depicts the distribution of first 
line pharmacotherapeutics used to treat the entire study cohort (n=147). The TKIs prescribed included pazopanib 
(n=67), sunitinib (n=27), cabozantinib (n=6), sorafenib (n=2), and axitinib (n=1). mTOR inhibitors prescribed 
included everolimus (n=5) and temsirolimus (n=2). The checkpoint inhibitor immunotherapy included 
monotherapy nivolumab (n=8) and combination therapy of ipilimumab and nivolumab (n=19). All instances of a 
TKI plus checkpoint inhibitor immunotherapy was axitinib plus pembrolizumab (n=3). Panel B depicts the 
distribution of anti-diabetic medications (n=39) for patients in the T2DM arm at the time first-line mRCC 
treatment was initiated. The sulfonylureas prescribed included glipizide (n=7) and glimepiride (n=2). The GLP-
1 agonists prescribed were exenatide (n=1), dulaglutide (n=2) and liraglutide (n=1), the DPP-4 inhibitors 
prescribed were sitagliptin (n=1) and linagliptin (n=1), and the thiazolidinedione prescribed was pioglitazone 
(n=1). Abbreviations: DPP-4, dipeptidyl peptidase-4; GLP-1, glucagon-like peptide-1; HD IL-2, high dose 
interleukin-2, mTOR, mammalian target of rapamycin, TKI, tyrosine kinase inhibitor; T2DM, type 2 diabetes 
mellitus; VEGF, vascular endothelial growth factor. 
   
Figure 3. RCC prognosis in T2DM and non-T2DM patients. Panel A depicts the difference in prevalence of 
mRCC diagnosis at presentation in the T2DM arm (n=27) and non-T2DM arm (n=120). Panel B shows the time 
from initial localized RCC diagnosis until progression with mRCC among the T2DM (n=17) and non-T2DM 
patients (n=62). Panel C shows the difference in PFS between the patient groups. Panel D shows the difference 
in OS between the two patient groups. Abbreviations: mRCC, metastatic renal cell carcinoma; OS, overall 




Figure 4. Subgroup analysis of PFS and OS. Panel A shows OS from date of initial diagnosis of RCC in 
patients who were initially diagnosed with localized RCC in the T2DM and non-T2DM groups. Panel B shows 
OS from date of diagnosis of mRCC in patients initially diagnosed with localized RCC in the T2DM and non-
T2DM groups. Panel C shows PFS from date of diagnosis of mRCC in patients initially diagnosed with localized 
RCC in the T2DM and non-T2DM groups. Panel D shows OS for patients diagnosed with de novo mRCC in the 
T2DM and non-T2DM groups. Panel E shows PFS for patients diagnosed with de novo mRCC in the T2DM and 
non-T2DM groups. Abbreviations: mRCC, metastatic renal cell carcinoma; OS, overall survival; PFS, 
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